Etanercept for the Treatment of Lupus Nephritis

NCT ID: NCT00447265

Last Updated: 2013-02-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-02-29
• Study Completion Date: 2009-03-31

Brief Summary

Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease in which the body's immune system attacks its own normal tissues. This abnormal autoimmune response can result in damage to many parts of the body, including the skin, joints, lungs, heart, brain, intestines, and kidneys. Kidney problems occur in 60-75 % of lupus patients. The development of lupus-related kidney disease (called lupus nephritis) is associated with an overall worse prognosis.

SLE is usually treated with drugs that try to block inflammation caused by the immune system. These treatments can create their own problems and they do not cure lupus. The drugs that are often used to treat lupus nephritis include prednisone (steroids), cyclophosphamide (Cytoxan), azathioprine (AZA or Imuran), and mycophenolate mofetil (MMF or Cellcept). The main purpose of this study is to evaluate the safety and tolerability of etanercept compared to placebo in combination with standard of care to treat individuals with active lupus nephritis.

Detailed Description

Kidney problems associated with lupus nephritis range from asymptomatic protein in the urine to rapidly progressive glomerulonephritis, leading to end-stage renal disease. The goal of therapies is to control kidney manifestations in order to avoid kidney failure, the occurrence of other medical problems and death.

The treatment of lupus nephritis remains problematic. Despite the use of currently available therapies, patients experience disease relapse. Over time, patients develop significant morbidity from the disease as well as from medications used for treatment.

Etanercept, a TNF inhibitor, is proposed as a potential treatment for lupus nephritis. TNF increases the number of reactive B and T cells. TNF levels can be elevated in lupus. Etanercept is believed to work by blocking inflammation, and it is hoped that it will lessen the signs and symptoms of lupus-related kidney disease.

The purpose of this study is to evaluate the safety and tolerability of etanercept compared to placebo in combination with standard therapy to treat individuals with mild or moderately active lupus nephritis.

This study will last 1 year. Participants will be randomly assigned to receive either etanercept or placebo in addition to their regular medications. Participants will self-administer 50 mg etanercept or placebo injections once a week. They will continue receiving their usual treatment with corticosteroids and either MMF, Mycophenolic Acid, or AZA. Treatment with study medication will occur for 24 weeks.

There will be a screening visit followed by a randomization visit, where subjects will receive and learn how to administer the study drug. Subjects will come to the clinic for 9 study visits. A physical exam and blood and urine collection will occur at most study visits. Participants will also be asked to complete a questionnaire on their health at most study visits. Subjects will be contacted by phone 5 times during the 24-week period to assess for adverse events and worsening disease status.

Conditions

Lupus Nephritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Etanercept

Participants in this group will self-administer 50 mg etanercept injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).

Group Type: EXPERIMENTAL

Etanercept

Intervention Type: DRUG

1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.

Lupus Treatment- Standard of Care

Intervention Type: DRUG

Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)

Placebo

Participants in this group will self-administer 50 mg placebo injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).

Group Type: PLACEBO_COMPARATOR

Lupus Treatment- Standard of Care

Intervention Type: DRUG

Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)

Placebo

Intervention Type: DRUG

Interventions

Etanercept

1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.

Intervention Type: DRUG

Lupus Treatment- Standard of Care

Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

Enbrel

Eligibility Criteria

Inclusion Criteria

• Meets at least 4 of the 11 American College of Rheumatology (ACR) 1982 Revised Criteria for the Classification of SLE
• Active lupus nephritis
• Currently has antibodies to double-stranded DNA (dsDNA)
• Currently receiving treatment consisting of at least 1.5 g/day of MMF OR at least 720 mg/day orally of Mycophenolic Acid OR at least 1.5 mg/kg once per day of AZA for lupus nephritis, for at least 28 days prior to study entry
• Stable medication regimen for at least 4 weeks prior to study entry
• Able and willing to self-administer study drug OR has a designated caregiver at home to administer study drug injections
• Willing to use acceptable forms of contraception for the duration of the study

Exclusion Criteria

• Moderately severe anemia
• Neutropenia
• Thrombocytopenia
• Blood creatinine levels greater than 3.0 mg/dl
• Positive PPD without ongoing treatment for at least 30 days prior to study entry
• Pulmonary fibrotic changes
• Active infections (e.g., HIV, hepatitis B virus [HBV], hepatitis C virus [HCV]) and/or serologic evidence of prior exposure to hepatitis B
• Received a live vaccine within 3 months prior to study entry
• Doubled serum creatinine levels within the 3 months prior to study entry OR end-stage kidney disease
• Dialysis-dependent end-stage kidney disease or membranous nephritis
• History of cancer. Individuals with a history of cervical carcinoma in situ and resected basal and squamous cell carcinomas of the skin are not excluded.
• Receiving prednisone greater than 20 mg/day or equivalent corticosteroid treatment
• Pulse intravenous methylprednisolone within 30 days prior to study entry
• Receiving immunosuppressive agents other than prednisone, MMF, Mycophenolic Acid, AZA, or hydroxychloroquine
• Oral or intravenous cyclosporine, leflunomide IVIG, or plasmapheresis within 3 months prior to study entry
• Current or previous cyclophosphamide treatment
• Use of other experimental agent within 90 days prior to study entry
• Severe, progressive, or uncontrolled kidney, liver, blood, stomach, lung, heart, or brain disease. Individuals with any of these conditions that are related to active SLE are not excluded.
• Previous use of rituximab within 12 months prior to study entry
• Previous or current exposure to any of the following: etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), or anakinra (Kineret)
• Meets New York Heart Association classification of congestive heart failure (CHF) Class III or greater
• History of myocardial infarction or ischemia
• Current or history of substance abuse
• Known hypersensitivity to any component of the study drug
• Poorly controlled or advanced diabetes mellitus
• History of multiple sclerosis, transverse myelitis, optic neuritis, or epilepsy
• History of noncompliance with other therapies
• Pregnancy or breastfeeding

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maria Dall'Era, MD

Role: STUDY_CHAIR

Division of Rheumatology, University of California, San Francisco

David Wofsy, MD

Role: STUDY_CHAIR

Department of Medicine, University of California, San Francisco

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

University of California at San Francisco

San Francisco, California, United States

University of Colorado Health Sciences Center

Aurora, Colorado, United States

Feinstein Institute for Medical Research NS-L1J Health System

Manhasset, New York, United States

University of Rochester

Rochester, New York, United States

Duke University Medical Center

Durham, North Carolina, United States

Countries

United States

References

Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004 Oct;50(10):3161-9. doi: 10.1002/art.20576.

Reference Type: BACKGROUND

PMID: 15476222 (View on PubMed)

De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus. 2005;14(12):931-7. doi: 10.1191/0961203305lu2240rr.

Reference Type: BACKGROUND

PMID: 16425572 (View on PubMed)

Mor A, Bingham CO 3rd, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol. 2005 Apr;32(4):740-3.

Reference Type: BACKGROUND

PMID: 15801034 (View on PubMed)

Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004 Sep;15(5):280-94. doi: 10.1080/09546630410017275.

Reference Type: BACKGROUND

PMID: 15370396 (View on PubMed)

Other Identifiers

DAIT ALN01

Identifier Type: -

Identifier Source: org_study_id